Hengrui Pharma reports strong Q1-Q3 2025 results, driven by innovation and partnerships.

𝐆𝐫𝐨𝐰𝐭𝐡 𝐨𝐟 𝐂𝐨𝐧𝐭𝐫𝐚𝐜𝐭 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐟𝐨𝐫 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐃𝐞𝐯𝐢𝐜𝐞𝐬 ➡ 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅: https://lnkd.in/d-BVcBU3 Therapeutic Device Contract Manufacturing Market Size is valued at US$ 55.2 Bn in 2024 and is predicted to reach US$ 175.7 Bn by the year 2034 at an 12.6% CAGR during the forecast period for 2025-2034. ▪ 𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞: ▪ Thermo Fisher Scientific ▪ Integer Holdings Corporation ▪ Flex. ▪ Celestica. ▪ Phillips Medisize ▪ Plexus Corp. ▪ NIPRO Corporation - Global ▪ Viant Technology ▪ West Pharmaceutical Services ▪ Synecco #TherapeuticDevices #ContractManufacturing #MedicalDevices #HealthcareInnovation

Drug Master file (DMF) submission to the USFDA: 1. China is continuously dominating DMF filings and holding the top position globally with 47.36% . It is clearly evident that they are regularly focusing investment in the pharma industry 2. India is holding the second position globally with 40.55%

In 2024, the US pharmaceutical industry spent $100 billion on R&D, contributing to a global total of $190 billion. With top pharma firms investing 25% of their revenues into innovation, affordability challenges and shifting reimbursement policies are set to reshape the landscape. These pressures are driving the digitization of R&D to boost productivity and reduce costs, while also prompting the relocation of R&D activities to emerging territories with alternative funding opportunities. Dive into our latest instalment of our Navigating Global Pharma Policy series to explore these critical trends and their impact on the industry: https://okt.to/xcLk8s #AMon #HealthcareTransformation #Researchanddevelopment

The July-September quarter of 2025 witnessed a significant surge in the pharma and healthcare sector, with 72 transactions totalling $3.5 billion, led by Torrent Pharma's $1.4 billion acquisition of a 46% stake in JB Chemicals #TorrentPharma #JBChemicals https://lnkd.in/dGTFk8F7

ARS Pharmaceuticals, Inc. (SPRY) - Hold: Strong growth momentum but seasonal headwinds ahead. This report follows ARS Pharmaceuticals’ Q3 2025 earnings call, where the company reported significant revenue growth driven by its product NEFI and unveiled strategic initiatives aimed at expanding market share. Despite the positive growth trajectory, management indicated potential seasonal declines in Q4, prompting a cautious outlook. Upcoming Catalysts: - Publication of NEFI Experience Program outcomes. - Launch of NEFI in Japan, expected this quarter. - Approval anticipated in Canada and China in 2026. - Phase IIb urticaria trial top-line data in mid-2026. #HealthCare #Earnings #Investing #SellSyde #StockMarket 2025-11-Mo 19:08:58 https://lnkd.in/e9rdu6dj

ARS Pharmaceuticals, Inc. (SPRY) - Hold: Strong growth momentum but seasonal headwinds ahead. This report follows ARS Pharmaceuticals’ Q3 2025 earnings call, where the company reported significant revenue growth driven by its product NEFI and unveiled strategic initiatives aimed at expanding market share. Despite the positive growth trajectory, management indicated potential seasonal declines in Q4, prompting a cautious outlook. Upcoming Catalysts: - Publication of NEFI Experience Program outcomes. - Launch of NEFI in Japan, expected this quarter. - Approval anticipated in Canada and China in 2026. - Phase IIb urticaria trial top-line data in mid-2026. #HealthCare #Earnings #Investing #SellSyde #StockMarket 2025-11-Mo 19:10:04 https://lnkd.in/e9rdu6dj

ARS Pharmaceuticals, Inc. (SPRY) - Hold: Strong growth momentum but seasonal headwinds ahead. This report follows ARS Pharmaceuticals’ Q3 2025 earnings call, where the company reported significant revenue growth driven by its product NEFI and unveiled strategic initiatives aimed at expanding market share. Despite the positive growth trajectory, management indicated potential seasonal declines in Q4, prompting a cautious outlook. Upcoming Catalysts: - Publication of NEFI Experience Program outcomes. - Launch of NEFI in Japan, expected this quarter. - Approval anticipated in Canada and China in 2026. - Phase IIb urticaria trial top-line data in mid-2026. #HealthCare #Earnings #Investing #SellSyde #StockMarket 2025-11-Mo 19:12:08 https://lnkd.in/e9rdu6dj

ARS Pharmaceuticals, Inc. (SPRY) - Hold: Strong growth momentum but seasonal headwinds ahead. This report follows ARS Pharmaceuticals’ Q3 2025 earnings call, where the company reported significant revenue growth driven by its product NEFI and unveiled strategic initiatives aimed at expanding market share. Despite the positive growth trajectory, management indicated potential seasonal declines in Q4, prompting a cautious outlook. Upcoming Catalysts: - Publication of NEFI Experience Program outcomes. - Launch of NEFI in Japan, expected this quarter. - Approval anticipated in Canada and China in 2026. - Phase IIb urticaria trial top-line data in mid-2026. #HealthCare #Earnings #Investing #SellSyde #StockMarket 2025-11-Mo 19:17:11 https://lnkd.in/e9rdu6dj

ARS Pharmaceuticals, Inc. (SPRY) - Hold: Strong growth momentum but seasonal headwinds ahead. This report follows ARS Pharmaceuticals’ Q3 2025 earnings call, where the company reported significant revenue growth driven by its product NEFI and unveiled strategic initiatives aimed at expanding market share. Despite the positive growth trajectory, management indicated potential seasonal declines in Q4, prompting a cautious outlook. Upcoming Catalysts: - Publication of NEFI Experience Program outcomes. - Launch of NEFI in Japan, expected this quarter. - Approval anticipated in Canada and China in 2026. - Phase IIb urticaria trial top-line data in mid-2026. #HealthCare #Earnings #Investing #SellSyde #StockMarket 2025-11-Mo 19:30:40 https://lnkd.in/e9rdu6dj

Comment, Share, & Like! Atlanta Lands $200M Pharma Plant. Pharmaceutical company ACG announced a $200 million phased investment to establish its first empty-capsule manufacturing operations in the United States. The initial $100 million will fund a hard-shell capsule facility in Atlanta, with a second phase of $100 million planned to expand capacity and capabilities in the region. The investment is expected to create more than 200 jobs, with operations targeted to begin in ... The post Atlanta Lands $200M Pharma Plant appeared first on Connect CRE. http://ow.ly/YPBi106oKyt #BCRE #FutureForward #Atlanta